Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Hypertension Complicated With Type 2 Diabetes
Interventions: iTHRIVE intervention, Active comparator; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Gaithersburg, Maryland

Conditions: Hypertension, Food Insecurity
Interventions: DASH-FV, nutrition counselling only; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Open Angle Glaucoma
Interventions: Suprachoroidal Dissection Instrument (SDI); Device
Lead sponsor: iScience Interventional Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Medication Adherence
Interventions: Peer Delivery of Medications, Health Information Technology (HIT) Platform; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
Interventions: Sanvar® (vapreotide); Drug
Lead sponsor: Debiovision; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 19
States / cities: Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 15 more

Conditions: Hypertension
Interventions: CIN-107, Matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypertension
Interventions: placebo, PF-00489791; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Los Angeles, California • Santa Ana, California • Tustin, California + 15 more

Conditions: Preeclampsia
Interventions: collection of maternal blood specimen prior to delivery, collection of placental cord blood after delivery, collection of placental tissue, collection of strip of decidua from uterine lining from cesarean section deliveries; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Metoprolol, Lisinopril, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 3
States / cities: Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas

Conditions: Hypertension in Pregnancy
Interventions: Home Blood Pressure Telemonitoring; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Healthy, Hypercholesterolemia, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma
Interventions: AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 18
States / cities: Inglewood, California • Petaluma, California • Poway, California + 15 more

Conditions: Neovascular Glaucoma
Interventions: Aflibercept; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Hypertension
Interventions: PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: San Francisco, California • New York, New York

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions: Placebo, LAM-001; Drug
Lead sponsor: IRulya Therapeutics Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more

Conditions: Hypertension
Interventions: Digital Coaching Plan, Health Awareness; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Hypertension
Interventions: Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 20,723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more

Conditions: Hypertension
Interventions: Levamlodipine, Amlodipine, Amlodipine, Levamlodipine; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Hypertension, Pulmonary
Interventions: Adempas (Riociguat, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 20 more

Conditions: Preeclampsia, Gestational Hypertension, Hypertension, Obesity, Overweight and Obesity, Pregnancy Complications, Pregnancy Toxemia, Postpartum Preeclampsia
Interventions: Home Blood Pressure Monitoring, Heart Health 4 New Moms, Usual care; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma
Interventions: SmartSystem VR Headset perimeter; Diagnostic Test
Lead sponsor: Andrew Pouw, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Atrial Fibrillation, Arterial Hypertension
Interventions: Redo PVI, PVI + RDN; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Resistant Hypertension
Interventions: Splanchnic Nerve Denervation, Renal Denervation Only; Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Integrating Free-choice Marketplace, dieTitian coacHing, cultuRally Tailored messagIng to improVE Blood Pressure

DASH Diet Intervention for Systemic Hypertension in Adolescents

Surgical Treatment of Refractory Open Angle Glaucoma

Peers and Technology for Adherence, Access, Accountability, and Analytics

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Emergency Department Home Blood Pressure Monitoring and BpTRU Study

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Gene Expression In Pregnancies Complicated by Preeclampsia

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

STAMPP-HTN in a High-risk Rural Population of Women

The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Investigating Behavior Change Methods for the Management of Hypertension

Diuretic Comparison Project

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter

Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI

The RESPLASH Study